The FDA has approved a combination of lurbinectedin and atezolizumab for maintenance therapy in extensive-stage small cell lung cancer. This approval is for first-line maintenance therapy, indicating it is intended for initial treatment. The combination has been approved under the brand names Zepzelca and Tecentriq, among others.